Article Information
Published By
Online ISSN
History
- Received December 24, 2021
- Accepted April 1, 2022
- Published online May 5, 2022.
Article Versions
- You are currently viewing a previous version of this article (May 5, 2022 - 08:49).
- View the most recent version of this article
Copyright & Usage
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Nigel S. Cook1,
- Gerard J. Criner2,
- Pierre-Régis Burgel3,4,
- Katie Mycock5,
- Tom Gardner6,14,
- Phil Mellor6,
- Pam Hallworth6,
- Kate Sully7,
- Sophi Tatlock7,
- Beyza Klein1,
- Byron Jones1,
- Olivier Le Rouzic8,9,
- Kip Adams10,
- Kirsten Phillips11,
- Mike McKevitt12,
- Kazuko Toyama13 and
- Florian S. Gutzwiller1⇑
- 1Novartis Pharma AG, Basel, Switzerland
- 2Temple University, Philadelphia, PA, USA
- 3Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
- 4Université de Paris and Institut Cochin, Inserm U1016, Paris, France
- 5Adelphi Real World, Cheshire, UK
- 6Adelphi Research, Cheshire, UK
- 7Adelphi Values, Cheshire, UK
- 8La Fondation du Souffle, Paris, France
- 9Univ. Lille, CHU Lille, Inserm U1019, Lille, France
- 10COPD Foundation, Miami, Florida, USA
- 11Lung Foundation, Australia, Brisbane, Queensland, Australia
- 12British Lung Foundation, England, UK
- 13J-Breath, Tokyo, Japan
- 14Employed by Adelphi when the study was conducted
- Corresponding author: Florian S. Gutzwiller (florian.gutzwiller{at}novartis.com)
Funding
Novartis Pharma AG, Basel, Switzerland
Article usage
Altmetrics
Vol 8 Issue 2
Table of Contents
People living with Moderate-to-Severe COPD Prefer Improvement of Daily Symptoms Over the Improvement of Exacerbations: A Multi-Country Patient Preference Study
